Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.

Breast cancer research and treatment - 1 May 2016

Paluch-Shimon Shani, Friedman Eitan, Berger Raanan, Papa Moshe, Dadiani Maya, Friedman Neil, Shabtai Moshe, Zippel Dov, Gutman Mordechai, Golan Talia, Yosepovich Ady, Catane Raphael, Modiano Tami, Kaufman Bella

Abstract excerpt

The purpose of this study was to assess pathological complete response and whether it serves a surrogate for survival among patients receiving neo-adjuvant doxorubicin-cyclophosphamide followed by paclitaxel for triple-negative breast cancer with respect to BRCA1 mutation status. From a neo-adjuvant systemic therapy database of 588 breast cancer cases, 80 triple-negative cases who had undergone BRCA genotyping...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Neoadjuvant Therapy

Share to Paclitaxel

Share to Survival Analysis

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 27113739
DOI: 10.1007/s10549-016-3800-5

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.PMID 27113739Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.Semantic proximity Read ↗

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Semantic proximity Read ↗

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.Semantic proximity Read ↗

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.Semantic proximity Read ↗

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.Semantic proximity Read ↗

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.Semantic proximity Read ↗

Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis.Semantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.